This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

dasatinib (Sprycel®)

Reference No. 1514

Publication date:

Appraisal information

dasatinib (Sprycel®) 20 mg film-coated tablet
dasatinib (Sprycel®) 50 mg film-coated tablet
dasatinib (Sprycel®) 80 mg film-coated tablet
dasatinib (Sprycel®) 100 mg film-coated tablet
dasatinib (Sprycel®) 140 mg film-coated tablet
dasatinib (Sprycel®) 70 mg film-coated tablet

Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 06/02/2019
AWMSG meeting date: 13/03/2019
Submission Type: Limited Submission
Status: Recommended
Advice No: 0319
Ratification by Welsh Government: 28/03/2019

Current Progress

Ratification by
Welsh Government

AWMSG advice

Dasatinib (Sprycel®) is recommended as an option for use within NHS Wales for the treatment of paediatric patients weighing ≥ 10 kg with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in chronic phase (Ph+CML-CP) or Ph+CML-CP resistant or intolerant to prior therapy including imatinib. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)